Angelman Syndrome

Etiology

Angelman syndrome is caused by 4 distinct molecular mechanisms, each involving loss of maternal UBE3A function but carrying different implications for phenotypic severity and recurrence risk.[2][3] 

Chromosome 15q11.2-q13 Deletions (70%-75% of Cases)

The most common mechanism involves de novo microdeletions spanning approximately 5 to 7 megabases (Mb). These deletions remove not only UBE3A but also contiguous genes, including GABRB3 (a GABA receptor subunit implicated in seizure susceptibility) and OCA2 (involved in melanin biosynthesis, accounting for hypopigmentation in individuals with deletions). These deletions occur in 2 principal classes: Class I deletions (BP1-BP3, approximately 5.9 Mb) and Class II deletions (BP2-BP3, approximately 5.0 Mb). Recurrence risk is less than 1% unless a maternal chromosomal rearrangement is present.[2]

Paternal Uniparental Disomy (3%-7% of Cases)

Both chromosome 15 homologs are inherited from the father, leaving no maternally derived UBE3A allele. Uniparental disomy (UPD) typically arises from trisomy rescue or monosomy correction. Recurrence risk remains below 1%.[2]

Imprinting Center Defects (3%-5% of Cases)

Pathogenic variants or microdeletions affecting the imprinting center prevent proper establishment of the maternal methylation pattern. Imprinting defects may be inherited, conferring a recurrence risk of up to 50% in carrier mothers.[2]

UBE3A Pathogenic Variants (5%-10% of Cases)

Single-nucleotide variants, small deletions, or insertions directly disrupt the UBE3A gene. These variants may be de novo or maternally inherited; carrier mothers face 50% recurrence risk.[2][6]

Approximately 3% to 10% of individuals meeting clinical criteria have no identifiable molecular abnormality despite comprehensive testing.[2]

Epidemiology

Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 live births, with some estimates suggesting a prevalence as high as 1 in 10,000. The condition occurs with equal frequency across sexes and all ethnic groups.[2][7] 

Diagnosis is typically established at a mean age of about 2 years; however, age at diagnosis varies by genotype, with deletion cases identified earlier (mean 1.7 years) than nondeletion cases (mean 2.9 years), reflecting the more distinctive phenotype associated with large deletions.[7]

Data from the Angelman Syndrome Natural History Study, which enrolled more than 450 individuals across North American sites, indicate the following distribution: 71% deletions, 7% paternal UPD, 11% UBE3A pathogenic variants, 3% imprinting defects, and the remainder with unknown mechanisms.[7][8]

Pathophysiology

Angelman syndrome results from the selective loss of functional UBE3A expression in the central nervous system, where the paternal allele is normally silenced and the maternal allele provides the sole source of UBE3A protein. UBE3A functions as an E3 ubiquitin ligase essential for proteasome–mediated protein degradation; loss of UBE3A results in altered synaptic transmission, impaired synaptic plasticity, and disrupted neural circuitry.[2]

The unique GABAergic dysfunction underlies multiple clinical manifestations, including seizure susceptibility, sleep disturbance, and behavioral features. Recent research has demonstrated that individuals with Angelman syndrome have significantly lower respiratory rates during sleep than age-matched controls, suggesting a fundamental dysfunction of respiratory control that reflects underlying GABAergic system abnormalities.[9]

Importantly, antisense oligonucleotide–mediated paternal UBE3A reactivation rescues sleep and electroencephalographic abnormalities even when administered in juvenile or adult mice, suggesting that UBE3A dysfunction remains amenable to therapeutic intervention throughout life.[5]

History and Physical

The clinical presentation follows a characteristic age-dependent evolution, as mentioned below.[2][10]

Infancy (0-12 months): Feeding difficulties are the earliest indicator, often due to poor sucking-swallowing coordination, tongue thrusting, and truncal hypotonia. Findings at birth are often unremarkable.

Late infancy to toddlerhood (6-36 months): Developmental delay typically becomes apparent by 6 to 12 months. Seizures generally appear between 1 and 3 years of age, affecting 80% of individuals by age 3. Relative microcephaly develops by age 2, particularly in patients with deletions. A characteristic happy demeanor, often marked by frequent and unprovoked laughter, also becomes evident over time.

Motor features: The gait, when achieved between ages 2.5 and 6, is characteristically ataxic and wide-based, with arms elevated and flexed. Approximately 10% of individuals never achieve independent walking. Three-dimensional gait analysis shows progressive worsening of a flexed-knee posture during childhood.[11]

Behavioral features: Easily provoked laughter and a happy demeanor are virtually universal. Additional characteristics include hand flapping; mouthing behaviors (95%); short attention span (87%); fascination with water or reflective surfaces (~75%), which may increase the risk of drowning; and hyperactivity, which typically diminishes with age.[2][10]

Speech and communication: Severe expressive speech impairment is universal, with up to 85% of individuals remaining essentially nonverbal. Receptive language exceeds expressive language.[2]

Seizures: Seizure onset typically occurs between ages 12 and 18 months. Reported seizure types include atonic, atypical absence, myoclonic, and generalized tonic-clonic seizures. Seizure burden often improves during puberty but may recur in adulthood.[2]

Sleep disturbances: Sleep disturbances affect 70% to 80% of individuals and are characterized by difficulty initiating and maintaining sleep, decreased sleep requirement, and abnormal circadian rhythm. Most individuals demonstrate markedly reduced nighttime melatonin levels.[2][9]

Physical features in deletion patients: Individuals with deletions commonly exhibit hypopigmentation, defined as lighter skin, hair, and eyes relative to family members, as well as a protruding tongue, wide mouth with widely spaced teeth, prognathism, frequent drooling, and strabismus.[2]

Evaluation

Molecular Diagnostic Algorithm for Angelman Syndrome

Diagnostic evaluation follows a stepwise molecular testing algorithm, with methylation analysis serving as the first-line investigation.[2][12]

• Step 1—Methylation analysis: Methylation-specific multiplex ligation–dependent probe amplification (MLPA) is performed as the initial test and detects approximately 80% of cases. An abnormal result confirms the diagnosis but does not specify the mechanism.
• Step 2—Deletion testing: If methylation analysis is abnormal, deletion testing is performed using chromosomal microarray, fluorescence in situ hybridization (FISH), or MLPA. Approximately 70% of all cases are deletion-positive.
• Step 3—Paternal uniparental disomy: If methylation analysis is abnormal but no deletion is identified, paternal UPD testing is performed using microsatellite analysis with parental samples. If negative, proceed to the imprinting center analysis.
• Step 4—UBE3A gene sequencing: If methylation is normal but clinical suspicion remains high, UBE3A gene sequencing with deletion or duplication analysis is performed. Pathogenic variants in UBE3A are associated with normal methylation patterns.

Electroencephalography

Characteristic abnormalities are observed in 80% to 96% of affected individuals. The most specific finding is notched delta activity, consisting of high-amplitude (200-250 µV) delta waves (2-4 Hz) with superimposed spikes, predominantly in the frontal regions. These findings may appear as early as 4 to 9 months. Delta rhythmicity has been validated as a biomarker correlating with UBE3A expression levels.[2][13]

Additional Assessments

Polysomnography can be used to characterize sleep architecture and detect respiratory dysfunction. The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4), and the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3), provide standardized assessments of developmental and adaptive functioning. Angelman syndrome–specific outcome measures, including the Symptoms of Angelman Syndrome–Clinician Global Impression (SAS-CGI) and Caregiver-reported Angelman Syndrome Scale (CASS), have been validated for use in clinical trials.[7][14]

Treatment / Management

Management requires a comprehensive, multidisciplinary approach. No disease-modifying therapies are currently approved; however, multiple investigational therapies have progressed to late-stage clinical development.[2][4](B3)

Seizure Management

Seizures affect 80% to 90% of individuals with Angelman syndrome. Epilepsy management involves specific medication considerations that differ substantially from standard epilepsy treatment.[2][15](B2)

Contraindicated medications: The agents below are contraindicated because of documented seizure worsening.[15][16][17](B2)

• Carbamazepine and oxcarbazepine are sodium channel blockers that aggravate absence and myoclonic seizures.
• Vigabatrin paradoxically induces or increases seizure frequency.
• Phenytoin worsens absence and myoclonic seizures.
• Tiagabine is considered potentially harmful according to consensus guidelines.

Preferred first-line medications: The agents below are recommended as first-line therapy for seizure control.[2][15][18](B2)

• Levetiracetam achieves greater than 90% seizure reduction in 86% of individuals.
• Clobazam achieves greater than 90% seizure reduction in 93% of individuals.
• Lamotrigine is particularly effective for atypical absence seizures.
• Topiramate is effective and provides additional weight management benefits.
• Ethosuximide is primarily indicated for absence seizures.

Valproate: Valproate is effective but is associated with motor adverse effects in more than 70% of patients. The 2022 consensus recommends its sparing use, except as a bridge medication or after failure of other anticonvulsants.[2](B3)

Dietary therapy: The low glycemic index treatment is associated with complete seizure freedom in 22% of individuals and seizure freedom, except during intercurrent illness, in an additional 43%.[19](B2)

Status epilepticus: Nonconvulsive status epilepticus occurs in 35% to 85% of patients. Rescue medications should be readily available for all patients.[2](B3)

Sleep Management

Sleep disturbances are common and contribute significantly to caregiver burden.

• Behavioral interventions are first-line and include consistent sleep hygiene practices, low-light evening environments, and enclosed sleeping arrangements.[2]
• Melatonin has demonstrated efficacy in randomized controlled trials. Doses of 0.3 to 5 mg reduce sleep latency by 32 minutes and increase total sleep time by 56 minutes.[20]
(A1)

Gastrointestinal Management

Gastrointestinal manifestations affect 86.5% of individuals. Constipation affects 80% to 85% of individuals and may contribute to increased seizure frequency. Gastroesophageal reflux disease affects 45% to 65% of individuals. The risk of aspiration necessitates evaluation by speech-language pathology services.[21]

Orthopedic Management

Scoliosis affects 20% of children and 50% of adults, and 24% of affected individuals require surgical intervention. Physical therapy improves mobility and helps prevent secondary complications.[2](B3)

Communication Intervention

Speech and language therapy, with an emphasis on augmentative and alternative communication, should be initiated at diagnosis. Systematic review evidence confirms the viability of alternative communication for enhancing communication.[22](A1)

Emerging Therapies (All Investigational)

Multiple disease-modifying therapies are currently advancing through clinical trials.[4][5][23]

Antisense Oligonucleotide Therapies

Antisense oligonucleotide therapies target UBE3A-ATS, a long noncoding RNA that silences the paternal UBE3A allele, leading to transcript degradation and restoration of UBE3A protein expression.

• GTX-102 (Ultragenyx): The Phase 3 ASPIRE trial fully enrolled 129 participants in July 2025, and results are expected in the second half of 2026.[NCT06617429] The therapy received FDA Breakthrough Therapy Designation in June 2025.[4] 
• ION582 (Ionis): The Phase 3 REVEAL study was initiated in early 2025.[NCT06914609] The therapy received FDA Breakthrough Therapy Designation in September 2025 and has not demonstrated lower extremity weakness [ION582 FDA Breakthrough Therapy Designation for Angelman Syndrome].
• Rugonersen (Oak Hill Bio): Phase 1 results demonstrated dose-dependent normalization of electroencephalography patterns in 61 children.[23]

Gene Therapy

MVX-220 (MavriX Bio): AAV9–mediated UBE3A gene replacement therapy is being evaluated in Phase 1/2 clinical trials,[NCT07181837] with the first patient dosed in 2025.[PR Newswire] MVX-220 has received FDA Orphan Drug Designation.[Angelman Network Research Updates]

Differential Diagnosis

Several neurodevelopmental disorders share similar clinical features with Angelman syndrome. The principal conditions are outlined below.[2]

• Rett syndrome (MECP2): This condition is characterized by regression after a period of normal development, hand stereotypies, and predominance in females.
• Pitt-Hopkins syndrome (TCF4): This condition is characterized by breathing abnormalities, including hyperventilation and apnea, as well as distinctive facies.
• Christianson syndrome (SLC9A6): This X-linked disorder is associated with cerebellar and brainstem atrophy on magnetic resonance imaging (MRI).
• Mowat-Wilson syndrome (ZEB2): This condition is characterized by Hirschsprung disease and distinctive facies.
• Kleefstra syndrome (EHMT1): This condition is characterized by distinctive facial features and a characteristic behavioral profile.
• Prader-Willi syndrome: This condition is characterized by loss of paternally expressed genes due to abnormal imprinting and presents with hypotonia, hyperphagia, obesity, and infrequent seizures.

Prognosis

Angelman syndrome is not degenerative. Overall health remains generally good, and affected individuals have a near-normal to normal life expectancy, with the oldest documented individual reaching 83 years of age.[8][10]

Outcomes vary substantially by genotype. Individuals with deletions demonstrate the most severe phenotype, characterized by earlier and more refractory seizures, absent speech, and greater motor impairment. By age 15, individuals with deletions have a 50% probability of acquiring 17 of 30 measured adaptive skills, compared with 25 of 30 skills among individuals without deletions.[8][10]

Leading causes of death vary by age, with seizures and accidents predominating in young children and pneumonia in older adults. Sudden unexpected death in sleep has also been reported as a cause of mortality.[24] Most adults require lifelong care and 24-hour supervision.[25] Seizures often improve during puberty but may recur in the third or fourth decades of life. Sleep generally improves with age, and hyperactivity diminishes. The characteristic happy demeanor typically persists throughout life.[2][10]

Complications

Epilepsy-related complications include treatment-resistant seizures (84% of individuals experience refractory epilepsy during early childhood), status epilepticus, and seizure-related injuries. Medication-related complications include motor deterioration associated with valproate and paradoxical seizure worsening associated with contraindicated agents.[2]

Orthopedic complications include progressive scoliosis requiring surgical intervention in approximately one-quarter of affected individuals, joint contractures, and decreased bone density.[2]

Aspiration pneumonia occurs secondary to gastroesophageal reflux disease, feeding difficulties, and excessive drooling and represents a major cause of hospitalization and mortality.[2][21]

Behavioral complications include self-injurious behavior (52% of adults), aggressive behavior, and anxiety that tends to worsen with age.[10]